Mehtap Boduc, M. Roessler, R. Mandic, Christoph Netzer, C. Güldner, U. Walliczek-Dworschak, M. Mandapathil
{"title":"头颈癌患者淋巴结转移灶中COX-2的存在及含量","authors":"Mehtap Boduc, M. Roessler, R. Mandic, Christoph Netzer, C. Güldner, U. Walliczek-Dworschak, M. Mandapathil","doi":"10.24983/SCITEMED.AOHNS.2017.00024","DOIUrl":null,"url":null,"abstract":"COX-2 expression in primary lesions, as well as lymph node metastases, appears to identify HNSCC patients at higher risk in all tumor sites. Adjuvant therapeutic approaches targeting COX-2 might be a promising tool in this patient population.","PeriodicalId":272593,"journal":{"name":"Archives of Otorhinolaryngology-Head & Neck Surgery","volume":"5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Presence and Quantity of COX-2 in Lymph Node Metastases of Patients with Head and Neck Cancer\",\"authors\":\"Mehtap Boduc, M. Roessler, R. Mandic, Christoph Netzer, C. Güldner, U. Walliczek-Dworschak, M. Mandapathil\",\"doi\":\"10.24983/SCITEMED.AOHNS.2017.00024\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"COX-2 expression in primary lesions, as well as lymph node metastases, appears to identify HNSCC patients at higher risk in all tumor sites. Adjuvant therapeutic approaches targeting COX-2 might be a promising tool in this patient population.\",\"PeriodicalId\":272593,\"journal\":{\"name\":\"Archives of Otorhinolaryngology-Head & Neck Surgery\",\"volume\":\"5 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Archives of Otorhinolaryngology-Head & Neck Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24983/SCITEMED.AOHNS.2017.00024\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Otorhinolaryngology-Head & Neck Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24983/SCITEMED.AOHNS.2017.00024","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Presence and Quantity of COX-2 in Lymph Node Metastases of Patients with Head and Neck Cancer
COX-2 expression in primary lesions, as well as lymph node metastases, appears to identify HNSCC patients at higher risk in all tumor sites. Adjuvant therapeutic approaches targeting COX-2 might be a promising tool in this patient population.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
